April 2, 2013
/PRNewswire/ -- Kalila Medical, a privately held medical device company focused on the development of next-generation steerable catheter technologies, today announced the issuance of U.S. Patent No. 8,323,241 by the US Patent and Trademark Office (USPTO), titled "Steerable Medical Delivery Devices and Methods of Use". The company's proprietary technology encompasses a novel catheter tip deflection system that offers the superior precision and control required for increasingly complex electrophysiology and endovascular procedures. Kalila is the exclusive licensee of the patent, which has been issued to its affiliate Shifamed, LLC.
"This patent is central to our truVector™ technology, which enables tip deflection of catheter systems without the use of traditional pull-wires," said
, President and CEO of Kalila Medical. "Pull-wire based catheter deflection systems have inherent limitations including poor torque response and 'whipping' of the catheter tip during rotation. The truVector™ technology solution is a first-of-its-kind coaxial system that substantially improves the performance of products such as steerable introducer sheaths."
"During an RF ablation procedure, precise and predictable torque response and tip positioning are crucial for a successful treatment; millimeter shifts can affect procedural outcomes," states Dr.
, an electrophysiologist from Palo Alto Medical Foundation in
Palo Alto, California
. "The truVector™ technology has the potential to offer control currently not available with other steerable sheaths."
The Vado™ Steerable Sheath is Kalila Medical's first product to utilize the proprietary truVector™ technology. Currently in the final stages of development, the Vado sheath is expected to be submitted for regulatory approval in the second half of 2013.
About Kalila Medical
Founded in 2010, Kalila Medical is a privately held medical device company, formed by Shifamed LLC, a Silicon Valley based medical device incubator. Kalila's first product, the Vado
Steerable Sheath, is redefining precision and control with an innovative platform of specialized delivery and access catheters. The procedural benefits of Kalila's proprietary truVector™ technology can be leveraged across a growing number of endovascular applications including atrial fibrillation ablation, mitral valve repair, ASD/PFO closure, left atrial appendage closure, transseptal puncture, and LV lead placement.
For more information please visit
SPRIG Consulting LLC(408) 805-0520
SOURCE Kalila Medical